A Multi-Center, 2-Part Study to Evaluate the Pharmacokinetics Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery [Estudio multicéntrico de 2 partes para evaluar la farmacocinética, la seguridad y la tolerabilidad del aprepitant en pacientes pediátricos sometidos a una intervención quirúrgica].

Trial Profile

A Multi-Center, 2-Part Study to Evaluate the Pharmacokinetics Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery [Estudio multicéntrico de 2 partes para evaluar la farmacocinética, la seguridad y la tolerabilidad del aprepitant en pacientes pediátricos sometidos a una intervención quirúrgica].

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Aprepitant (Primary) ; Ondansetron
  • Indications Postoperative nausea and vomiting
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Oct 2012 Planned End Date changed from 1 Nov 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov record.
    • 10 May 2012 Planned End Date changed from 1 Jul 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top